TGA extends the use of Bayer contraceptive to eight years

This is a preview of subscriber content

Subscribe now to continue reading.

Manoj Saxena, CEO of Bayer Australia and New Zealand and country division head for the Pharmaceutical Division, said, “As a leading company in women’s healthcare, Bayer is committed to offering modern innovations as well as advances in the use of trusted products like Mirena, which has been used in Australia for more than 20 years." …

Subscribe now to continue reading.

TGA extends the use of Bayer contraceptive to eight years

This is a preview of subscriber content

Latest Video

Most Read

In 2025, the US is more likely to adopt PBS pricing policies than oppose them

Women's health listings spark debate over the timing of a ministerial 'nudge'

Doctor group changes position on weight-loss therapies and the PBS

TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer

AstraZeneca and Alexion secure back-to-back 'Pharma Cup' victory

New Stories

Nyrada commences recruitment for phase one clinical trial

Neurizon Therapeutics updates investors on initiatives to lift clinical hold

Radiopharm Theranostics says new data confirms positive tumour uptake

Race secures ethics approval for RC220 Phase 1 solid tumour trial

TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer

Doctor group changes position on weight-loss therapies and the PBS

In 2025, the US is more likely to adopt PBS pricing policies than oppose them

Sign In

TGA extends the use of Bayer contraceptive to eight years

This is a preview of subscriber content

Latest Video

Most Read

In 2025, the US is more likely to adopt PBS pricing policies than oppose them

Women's health listings spark debate over the timing of a ministerial 'nudge'

Doctor group changes position on weight-loss therapies and the PBS

TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer

AstraZeneca and Alexion secure back-to-back 'Pharma Cup' victory

Follow Us

New Stories

Nyrada commences recruitment for phase one clinical trial

Neurizon Therapeutics updates investors on initiatives to lift clinical hold

Radiopharm Theranostics says new data confirms positive tumour uptake

Race secures ethics approval for RC220 Phase 1 solid tumour trial

TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer

Doctor group changes position on weight-loss therapies and the PBS

In 2025, the US is more likely to adopt PBS pricing policies than oppose them